Healthcare firms perform well in subdued US IPO market in 2024 BioAge's azelaprag is being developed in combination with GLP-1 drugs Proceeds from IPO to advance azelaprag into late-stage studies ...

Si has vuelto a la ciudad, toca mimar la piel para este cambio y apostar por cremas faciales antipolución. Hemos elaborado una selección con algunas de nuestras favoritas que puedes conseguir ya ...

Obesity drug developer BioAge Labs (BIOA) has filed regulatory filings as part of its U.S. IPO. It seeks to offer 7.5M shares at a price range of $17 to $19, implying a valuation of up to $602M at ...

BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking to raise as much as $157.5 million in its initial public offering and a ...

Aunque puedas pensar que no son necesarias, lo cierto es que ninguna rutina facial debería prescindir de una buena crema de noche. Estos tratamientos están diseñados específicamente para ...

(Reuters) - Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States, according to a ...

Dietas. Mar Mira, médico estético y nutricionista: "El yogur ayuda a combatir las bolsas en los ojos" Maquillaje. Xabi Rodrigues, maquillador de MAC: ""El colorete marrón rosado nunca falla ...

BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, has filed for an initial public offering. The company said Tuesday in a filing with ...

(Reuters) - Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States, according to a regulatory ...